Pierre-Régis Burgel, Jean-Louis Paillasseur, Isabelle Durieu, Martine Reynaud-Gaubert, Rebecca Hamidfar, Marlène Murris-Espin, Isabelle Danner-Boucher, Raphaël Chiron, Sylvie Leroy, Benoit Douvry, Dominique Grenet, Laurent Mely, Sophie Ramel, Sylvie Moncouquiol, Espérie Burnet, El Hassane Ouaalaya, Philippe Sogni, Jennifer Da Silva, Clémence Martin
RATIONALE: Limited data exist on safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. OBJECTIVE: To evaluate the effects of ETI in an unselected population of pwCF and advanced lung disease. METHODS: A prospective observational study, including all adults, aged 18 years and older, with a percent predicted FEV1 (ppFEV1)≤ 40 who initiated ETI from December 2019 to June 2021 in France was conducted...
April 5, 2024: Annals of the American Thoracic Society